Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

4 Strengths and 4 Weaknesses to Know With Lucid Stock

By Larry Ramer, InvestorPlace Contributor

Lucid's CEO has a great resume, but the automaker is facing tough competition and LCID stock has lost momentum recently.

With Progress on Multiple Fronts, Bionano Genomics Stock Is Great Buy Here

By Larry Ramer, InvestorPlace Contributor

Bionano's acquisition of a software company makes Saphyr more attractive, and studies should result in insurers reimbursing those who use the system. BNGO stock is a buy.

Ford Has Strong Present and Future Catalysts

By Larry Ramer, InvestorPlace Contributor

F stock is very cheap, while Ford is benefiting from multiple, positive catalysts that should intensify over the long-term.

3 Tech Penny Stocks That Could Rocket in 2022

By Larry Ramer, InvestorPlace Contributor

These three tech penny stocks may deliver very high returns for patient, long-term investors. They all have cutting-edge products and low valuations.

With BlackBerry’s Auto App Store Progressing, BB Stock Is a Buy

By Larry Ramer, InvestorPlace Contributor

BlackBerry is poised to unveil its auto app store in early January. The news should be quite positive for BB stock.

Cassava Is a Sell After Accusations of Data Manipulation

By Larry Ramer, InvestorPlace Contributor

After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock.

Affirm Stock May Have a Bright Future, But It Is Already Priced In

By Larry Ramer, InvestorPlace Contributor

Facing very tough competition and losing a great deal of money, Affirm is not an appealing name. Investors should sell AFRM stock.

Ocugen Stock Looks Poised to Take a Tumble Right Here

By Larry Ramer, InvestorPlace Contributor

After WHO granted Covaxin a limited Emergency Use Listing, many institutions and hedge funds are likely to sell or short OCGN stock.

Roku Stock Is Poised to Bounce Back

By Larry Ramer, InvestorPlace Contributor

The fundamentals of Roku and ROKU stock remain very strong, and its valuation is attractive, making the shares worth buying for long-term investors.

Digital World Acquisition Corp. Stock Could Surprise on the Strength of Picking Up Truth Social

By Larry Ramer, InvestorPlace Contributor

Truth Social, the social network of former President Donald Trump, looks poised to be quite lucrative. As a result, DWAC stock appears to be undervalued.

Load More